The Relist Watch column examines cert petitions that the Supreme Court has “relisted” for its upcoming conference. A short explanation of relists is available here. There was a lot of action among the relisted cases at last week’s Supreme Court conference. The court granted review in six-time relis
Today, the Supreme Court again disregarded the views of the Federal government regarding whether to grant certiorari, here in Teva Pharmaceuticals USA v. GlaxoSmithKline LLC, and in.
The U.S. Supreme Court on
Monday declined to hear Teva Pharmaceuticals USA Inc s
challenge to a $235 million award to GlaxoSmithKline LLC
in a patent dispute over generic drugs involving a. | May 15, 2023